Jennifer Robinson
Investor Relations Contact bij VERVE THERAPEUTICS, INC.
Profiel
Jennifer Robinson is currently the Vice President of Investor Relations & Communications at Verve Therapeutics, Inc. Prior to her current position, she worked as the Senior Director of Investor Relations at Dyax Corp.
from 2014 to 2016, and as the Senior Director of Investor Relations at Ra Pharmaceuticals, Inc. and resTORbio, Inc. She also served as the Vice President of Investor Relations & Communications at Deciphera Pharmaceuticals, Inc. Ms. Robinson received her undergraduate degree from Dartmouth College.
Actieve functies van Jennifer Robinson
| Bedrijven | Functie | Begin |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Investor Relations Contact | - |
Eerdere bekende functies van Jennifer Robinson
| Bedrijven | Functie | Einde |
|---|---|---|
| DYAX CORP. | Investor Relations Contact | 01-04-2016 |
| RA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| DECIPHERA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| ADICET BIO, INC. | Investor Relations Contact | - |
Opleiding van Jennifer Robinson
| Dartmouth College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |